ONCAlert | Upfront Therapy for mRCC

EGFR+ Lung Cancer MORE >>

The combination of erlotinib and ramucirumab showed better progression-free survival in patients with newly diagnosed EGFR-mutant metastatic non–small cell lung cancer compared with erlotinib plus placebo, based on findings from the RELAY trial presented during the 2019 ASCO Annual Meeting. 

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.